Abstract

We present a pilot study on vascular targeting drug combretastatin A4-phosphate (CA4P) in K1735 malignant melanoma tumor models. Results show that CA4P induces a drastic decrease in blood flow and oxygen saturation.

© 2006 Optical Society of America

PDF Article